Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...

Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...

Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...

Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.